iVigee Services
iVigee » Do You Really Need a Safety Database Yet?

Do You Really Need a Safety Database Yet?

When a biotech company starts preparing for clinical trials, one of the questions that often comes up is which pharmacovigilance safety database to implement.

It’s an important decision, but it may not be the first one a company needs to make.

Before comparing systems, companies need to understand their product, their clinical development plans, and what their pharmacovigilance requirements will look like as they progress through development. Without that understanding, it’s easy to focus on selecting a database before knowing when it will actually be needed or what it needs to support.

The right starting point is a roadmap, not a software decision.

The database matters. But the experience behind it matters more.

There are several pharmacovigilance safety databases available, and many are capable of meeting the necessary requirements. The system itself is only one part of the decision.

What matters is understanding what regulations require and how the database fits into the company’s wider clinical, pharmacovigilance, and digital roadmaps. Those requirements will evolve as a product moves from a Phase 1 clinical trial toward commercialization.

This is where experience makes a difference.

If multiple vendors offer the same systems and all claim to have implementation experience, how do you decide who is right for your business?

Dr. Henry Seto, iVigee’s Chief Medical Officer, makes an interesting comparison with surgery. You might have the same tools, the same hospital, and even the same staff, but you would still want the surgeon with the best outcomes for your patient.

The same principle applies to pharmacovigilance. Knowing how to implement a particular database is one thing. Knowing how to plan, manage, and deliver an implementation in the context of a company’s development journey is another.

Why the timing of your safety database matters

Vijeet Goel, iVigee’s Executive Director, Head of Pharmacovigilance Systems, shares two examples that show why planning matters: two clinical-stage companies that approached their safety database requirements very differently.

The first company requested a roadmap at Phase 1. This meant the database could be planned and implemented at the right point in its development, rather than becoming an urgent requirement later.

The second company approached the process just three months before its clinical trial was due to start. Contracting, implementation, and FDA E2B(R3) gateway qualification were all still outstanding.

Both companies needed a safety database. The difference was when they started planning for it.

In the second case, the challenge wasn’t simply selecting the right system. It was fitting everything that needed to happen into an increasingly tight timeframe.

This is why waiting until a database becomes an immediate requirement can create unnecessary pressure. Understanding the regulatory and operational requirements early gives companies a clearer picture of what needs to happen and when.

Start with a pharmacovigilance roadmap

For companies approaching their first clinical trial, choosing a pharmacovigilance safety database doesn’t have to be the starting point.

A basic roadmap can help establish:

  • What the product and clinical development plans require.
  • When a safety database will be needed.
  • How the database fits into the wider clinical, PV, and digital strategy.
  • What needs to be considered ahead of implementation, including regulatory requirements and gateway qualification.

The objective isn’t to implement a system earlier than necessary. It’s to understand what will be required, avoid unnecessary delays, and make sure the right solution is ready when the business needs it.

A roadmap doesn’t have to be a major investment, but it can make a significant difference to how smoothly the process unfolds.

At iVigee, we believe the conversation should start with understanding your product and your plans, not simply deciding which database to buy.

If your company is approaching clinical trials and hasn’t established a safety database before, now is a good time to start that conversation.

By Gemma Dailly
Marketing Director
Gemma Dailly is Marketing Director at iVigee and a seasoned marketing professional with extensive experience across clinical research and healthcare technology. Having held senior marketing roles at CluePoints and AARDEX Group, she specialises in building high-growth brands, developing strategic marketing programmes, and turning complex industry challenges into compelling stories that resonate with customers and stakeholders alike.
iVigee » Do You Really Need a Safety Database Yet?
CONTACT IVIGEE

Have a PV challenge or question?

Free, with no obligation. Our team reads every message and replies personally within 48 hours.
CONTACT IVIGEE

Have a PV challenge or question?

Free, with no obligation. Our team reads every message and replies personally within 48 hours.
FEATURED CONTENT

Keep reading

Expert insights on pharmacovigilance, from AI in PV and inspection readiness to regulatory intelligence and signal management.
FREE PV BRIEFING

The PV briefing trusted by drug safety professionals.

In Signal Watch, our weekly LinkedIn newsletter, our physician-led team breaks down the latest regulatory changes, shares expert commentary, and gives you the practical insight you need to stay compliant and confident.

Subscribe now to stay in the loop.

iVigee Services, a.s.

Hvezdova 1716/2b, 140 00 Prague 4, Czech Republic

iVigee USA LLC

1500 District Avenue, Burlington, MA, United States

[email protected]

Book a Consultation

Tell us a little about what you need and one of our experts will be in touch within 48 hours.

We look forward to discussing AI in pharmacovigilance with you in more detail.
Marketing Consent*